CAS 1111556-37-6

Formula: C18H18N4O2

InChI: InChI=1S/C18H18N4O2/c1-2-10-22-15-9-4-3-8-14(15)20-18(22)21-17(24)13-7-5-6-12(11-13)16(19)23/h3-9,11H,2,10H2,1H3,(H2,19,23)(H,20,21,24)

InChI key: UOZVVPXKJGOFIG-UHFFFAOYSA-N

SMILES: CCCN1C2=CC=CC=C2N=C1NC(=O)C3=CC=CC(=C3)C(=O)N

Takinib

CAS: 1111556-37-6

Takinib

Formula: C₁₈H₁₈N₄O₂

Purity: ≥98%

Color and Shape: Solid

Molecular weight: 322.36

Ref: 54-BUP06020

1-N-(1-propyl-1H-1,3-benzodiazol-2-yl)benzene-1,3-dicarboxamide

CAS: 1111556-37-6

Formula: C₁₈H₁₈N₄O₂

Purity: 98%

Color and Shape: Solid

Molecular weight: 322.3611

Ref: IN-DA01DUZB

Takinib

CAS: 1111556-37-6

Takinib (EDHS-206) is a specific and effective TAK1 inhibitor(IC50= 9.5 nM).

Formula: C₁₈H₁₈N₄O₂

Purity: 98.29% - 99.65%

Color and Shape: White Solid

Molecular weight: 322.3611

Ref: TM-T4264

Takinib

CAS: 1111556-37-6

N1-(1-Propyl-1H-benzo[d]imidazol-2-yl)isophthalamide

Formula: C₁₈H₁₈N₄O₂

Purity: 98%

Molecular weight: 322.36

Ref: IN-DG00826306

Takinib

Controlled Product

CAS: 1111556-37-6

Takinib is a small molecule that is being developed as a treatment for inflammatory bowel disease (IBD). Takinib inhibits the production of pro-inflammatory factors, including cytokines and chemokines. It also reduces the proliferation of cancer cells. Takinib has been shown to be effective in inhibiting cisplatin-induced nephrotoxicity in vivo. It has also been shown to inhibit angiogenesis by suppressing the expression of vascular endothelial growth factor (VEGF) and to induce apoptosis in activated T cells. The molecule also inhibits the expression of molecules such as tumor necrosis factor alpha (TNFα), interleukin 6 (IL6), and monocyte chemoattractant protein 1 (MCP1). The drug's effectiveness against IBD has been demonstrated in a number of clinical trials. The drug has an effective dose of 10mg/kg/day, which is administered orally for up to 12 weeks.

Formula: C₁₈H₁₈N₄O₂

Purity: Min. 95%

Molecular weight: 322.36 g/mol

Ref: 3D-LUB55637